This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.
MASTERPLAN: A randomised phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease.
|Eligibility criteria|| |
|Study details|| |
Arm A: Control (40 patients): Standard of care chemotherapy.
Arm B: Investigational (80 patients): Standard of care chemotherapy with the addition of SBRT.
|Further information|| |
For more information regarding this clinical trial click here.